Omega Diagnostics Group (LON:ODX)‘s stock had its “corporate” rating reiterated by equities research analysts at FinnCap in a research note issued to investors on Wednesday, November 29th. They currently have a GBX 30 ($0.40) target price on the stock. FinnCap’s price target would indicate a potential upside of 72.02% from the stock’s current price.
Omega Diagnostics Group (ODX) opened at GBX 17.44 ($0.23) on Wednesday. Omega Diagnostics Group has a 12 month low of GBX 15.25 ($0.20) and a 12 month high of GBX 28.01 ($0.37).
ILLEGAL ACTIVITY NOTICE: This piece was first posted by American Banking News and is the property of of American Banking News. If you are accessing this piece on another website, it was illegally stolen and republished in violation of international trademark & copyright laws. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/12/31/omega-diagnostics-groups-odx-corporate-rating-reiterated-at-finncap.html.
Omega Diagnostics Group Company Profile
Omega Diagnostics Group PLC is a medical diagnostics company. The Company’s segments are Allergy and Autoimmune; Food Intolerance; Infectious/Other, and Corporate. Its product categories include allergy, anemia, autoimmunity, fertility and growth hormones, food intolerance, infectious disease, inflammation, quality control, thyroid hormones and tumor markers.
Receive News & Ratings for Omega Diagnostics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omega Diagnostics Group and related companies with MarketBeat.com's FREE daily email newsletter.